MX2023006205A - Tratamiento y diagnostico fotodinamico. - Google Patents

Tratamiento y diagnostico fotodinamico.

Info

Publication number
MX2023006205A
MX2023006205A MX2023006205A MX2023006205A MX2023006205A MX 2023006205 A MX2023006205 A MX 2023006205A MX 2023006205 A MX2023006205 A MX 2023006205A MX 2023006205 A MX2023006205 A MX 2023006205A MX 2023006205 A MX2023006205 A MX 2023006205A
Authority
MX
Mexico
Prior art keywords
phyllochlorin
analogues
pharmaceutically acceptable
diagnosis
acceptable salts
Prior art date
Application number
MX2023006205A
Other languages
English (en)
Inventor
Honsue Cho
Andrew N Stephens
Sebastian M Marcuccio
Christopher D Donner
Kieran P Stockton
Colin Skene
Jonathan Faber
Original Assignee
Rmw Cho Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rmw Cho Group Ltd filed Critical Rmw Cho Group Ltd
Publication of MX2023006205A publication Critical patent/MX2023006205A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0076—PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0036—Porphyrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic Table
    • C07F3/06—Zinc compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0659—Radiation therapy using light characterised by the wavelength of light used infrared
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0662—Visible light
    • A61N2005/0663—Coloured light

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Radiation-Therapy Devices (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención está relacionada con análogos de la filoclorina y sus sales farmacéuticamente aceptables, y con composiciones que comprenden análogos de la filoclorina y sus sales farmacéuticamente aceptables. Los análogos de la filoclorina y sus sales farmacéuticamente aceptables son adecuados para el uso en el tratamiento fotodinámico, tratamiento citoluminiscente y diagnóstico fotodinámico, por ejemplo, para tratar o detectar un tumor, o para el tratamiento antiviral. La presente invención también está relacionada con el uso de análogos de la filoclorina y sus sales farmacéuticamente aceptables en la fabricación de un agente fototerapéutico o de fotodiagnóstico y con un método de tratamiento fotodinámico, tratamiento citoluminiscente y diagnóstico fotodinámico, por ejemplo, para tratar o detectar un tumor, o para el tratamiento antiviral. (ver Fórmulas).
MX2023006205A 2020-11-26 2021-11-26 Tratamiento y diagnostico fotodinamico. MX2023006205A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2018667.2A GB202018667D0 (en) 2020-11-26 2020-11-26 Photodynamic therapy and diagnosis
PCT/EP2021/083253 WO2022112537A1 (en) 2020-11-26 2021-11-26 Photodynamic therapy and diagnosis

Publications (1)

Publication Number Publication Date
MX2023006205A true MX2023006205A (es) 2023-07-20

Family

ID=74099827

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023006205A MX2023006205A (es) 2020-11-26 2021-11-26 Tratamiento y diagnostico fotodinamico.

Country Status (11)

Country Link
US (1) US20230365577A1 (es)
EP (1) EP4251627A1 (es)
JP (1) JP2023552740A (es)
KR (1) KR20230147042A (es)
CN (1) CN116724043A (es)
AU (1) AU2021388872C1 (es)
CA (1) CA3199991A1 (es)
GB (1) GB202018667D0 (es)
IL (1) IL303068A (es)
MX (1) MX2023006205A (es)
WO (1) WO2022112537A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202217864D0 (en) * 2022-11-28 2023-01-11 Rmw Cho Group Ltd Novel compounds
GB202217863D0 (en) * 2022-11-28 2023-01-11 Rmw Cho Group Ltd Novel compounds
WO2024115524A1 (en) * 2022-11-28 2024-06-06 Rmw Cho Group Limited Porphyrin and phosphonium-porphyrin based compounds for photodynamic therapy and diagnostics

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0323358D0 (en) * 2003-10-06 2003-11-05 Green Grass Design Ltd Novel compounds and processes
AU2013357030B2 (en) * 2012-12-14 2018-03-29 Rmw Cho Group Limited Chlorin derivative useful in photodynamic therapy and diagnosis
US9951081B1 (en) * 2016-10-26 2018-04-24 Hui Liu Chlorin e6 derivative and pharmaceutically acceptable salt thereof and process for preparing and use of the same

Also Published As

Publication number Publication date
AU2021388872C1 (en) 2023-06-22
CN116724043A (zh) 2023-09-08
KR20230147042A (ko) 2023-10-20
AU2021388872A1 (en) 2022-09-22
GB202018667D0 (en) 2021-01-13
IL303068A (en) 2023-07-01
AU2021388872B2 (en) 2023-03-16
EP4251627A1 (en) 2023-10-04
JP2023552740A (ja) 2023-12-19
WO2022112537A1 (en) 2022-06-02
CA3199991A1 (en) 2022-06-02
US20230365577A1 (en) 2023-11-16

Similar Documents

Publication Publication Date Title
MX2023006205A (es) Tratamiento y diagnostico fotodinamico.
MX2021002886A (es) Terapia de combinacion para el tratamiento de cancer de mama triple negativo.
JOP20200315A1 (ar) مركبات بورينون واستخدامها في معالجة السرطان
FI3157527T3 (fi) Ezh2-inhibiittoreita lymfoman hoitoon
MX2021010173A (es) Compuestos con actividad inductora de ferroptosis y métodos de uso.
HK1078771A1 (en) Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiationin the treatment of cancer
PH12020551597A1 (en) Treatment of hidradenitis suppurativa using jak inhibitors
MX2020008906A (es) Compuestos con actividad inductora de ferroptosis y métodos de uso de estos.
NO20050450L (no) Kombinasjon av ZD6474, en inhibitor av vaskulaer endotelial vekst faktor reseptor, med radioterapi ved behandling av kreft
WO2018102687A3 (en) Combination therapy for treating cancer
MX2023004156A (es) Terapia combinada para el tratamiento del cancer.
MX2007005356A (es) Terapia de combinacion que comprende zd6474 y un antiadrogenico.
MX2022012351A (es) Administracion conjunta de mirdametinib y lifirafenib para uso en el tratamiento de canceres.
MX2022006853A (es) Macrociclos para uso en el tratamiento de enfermedades.
EA202193276A1 (ru) Способы лечения холангиокарциномы
HK1096023A1 (en) Combination therapy with azd2171 and 5-fu and/or cpt-11 azd2171?5-fu?cpt-11
MX2019002121A (es) Tratamiento conjunto para tratar el cancer de pancreas.
MX2021008928A (es) Métodos para mejorar la protección contra lesiones vasculares y de organos, la recuperación hematopoyética y la supervivencia en respuesta a la radiacion corporal total/exposicion química.
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.
BRPI0508959A (pt) uso de azd2171 ou de um sal do mesmo farmaceuticamente aceitável, uso de sal maleato de azd2171 e oxaliplatina, composição farmacêutica, kit, e, método para a produção de um efeito antiangiogênico e/ou de redução da permeabilidade vascular em um animal de sangue quente
MX2022011888A (es) Tratamiento de trastornos respiratorios.
MX2022008216A (es) Tratamiento de cancer en combinacion usando un antagonista de pd-1, un antagonista de ilt4 y lenvatinib o sales del mismo.
MX2022010093A (es) Tafoxiparina para el tratamiento de la preeclampsia.
BRPI0412408A (pt) métodos para a produção de um efeito de redução antiangiogênico e/ou de permeabilidade vascular e para o tratamento de um cáncer em um animal de sangue quente tal como um ser humano, composição farmacêutica, kit, e uso de azd2171 ou um sal farmaceuticamente aceitável deste e zd1839 ou um sal farmaceuticamente aceitável deste
MX2020007404A (es) Metodos y terapia de combincion para tratar cancer.